Michael DeWitt Culler
26Patents
9h-index
31Co-inventors
75Inventor score
Filing activity: Feb 3, 1984 → Aug 22, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4562175A | Synthetic peptides | Emerging Cross-Sectional Technologies | 24 | Expired |
| US7579435B2 | Somatostatin-dopamine chimeric analogs | Human Necessities | 22 | Expired |
| US7572883B2 | Somatostatin-dopamine chimeric analogs | Human Necessities | 17 | Expired |
| US7517853B2 | Somatostatin-dopamine chimeric analogs | Emerging Cross-Sectional Technologies | 17 | Expired |
| US8178651B2 | Somatostatin-dopamine chimeric analogs | Human Necessities | 16 | Active |
| US8324386B2 | Somatostatin-dopamine chimeric analogs | Human Necessities | 16 | Active |
| US6268342A | Method of inhibiting fibrosis with a somatostatin agonist | Human Necessities | 13 | Expired |
| US8822442B2 | Somatostatin-dopamine chimeric analogs | Emerging Cross-Sectional Technologies | 12 | Active |
| US9155777B2 | Use of melanocortins to treat insulin sensitivity | Chemistry; Metallurgy | 9 | Active |
| US6787521B2 | Method of inhibiting fibrosis with a somatostatin agonist | Human Necessities | 8 | Expired |
| US5686418A | Prolonging survival of transplanted pancreatic cells | Human Necessities | 7 | Expired |
| US8076281B2 | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment | Human Necessities | 5 | Active |
| US8236762B2 | Peptide-cytotoxic conjugates | Human Necessities | 4 | Active |
| US5972893A | Method of treating hyperprolactinemia and prolactinomas | Human Necessities | 3 | Expired |
| US8871706B2 | Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue | Emerging Cross-Sectional Technologies | 3 | Active |
| US7084117B2 | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof | Human Necessities | 3 | Expired |
| US5472856A | Recombinant human thymopoietin proteins and uses therefor | Chemistry; Metallurgy | 2 | Expired |
| US8741835B2 | Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment | Human Necessities | 2 | Active |
| US6342479B1 | Prolonging survival of transplanted pancreatic cells | Human Necessities | 2 | Expired |
| US5591588A | Method for the diagnosis of depression based on monitoring blood levels of arginine vasopressin and/or thymopoietin | Emerging Cross-Sectional Technologies | 1 | Expired |
| US8258094B2 | Analogs of ghrelin | Emerging Cross-Sectional Technologies | 1 | Active |
| US7238666B2 | Method of inhibiting fibrosis with a somatostatin agonist | Human Necessities | 0 | Expired |
| US5593842A | Method of measuring thymopoietin proteins in plasma and serum including acidification of the plasma and serum | Emerging Cross-Sectional Technologies | 0 | Expired |
| US9439943B2 | Use of melanocortins to treat insulin sensitivity | Chemistry; Metallurgy | 0 | Active |
| US7094753B2 | Somatostatin analog and uses thereof | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.